Provectus Biopharmaceuticals Launches VisiRose for Ophthalmic Therapies
Key Insights
Provectus Biopharmaceuticals (search) has launched VisiRose (search), a new entity focused on Rose Bengal Photodynamic Antimicrobial Therapy (search) (RB PDAT) for eye infections.
VisiRose (search) will commercialize RB PDAT, combining Rose Bengal Sodium (RBS) with a light-based device for infectious keratitis (search) and other serious eye infections.
The University of Miami is a minority equity shareholder, with the therapy based on research from Bascom Palmer Eye Institute.
Provectus Biopharmaceuticals (search), Inc. has announced the launch of VisiRose (search), Inc., a clinical-stage biotechnology company focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (search) (RB PDAT) for infectious keratitis (search) and other serious eye infections. This initiative aims to address unmet needs in ophthalmology using Provectus’s Rose Bengal Sodium (RBS) and innovative light-based technology. The University of Miami is a minority equity shareholder in VisiRose.
RB PDAT: A Novel Approach to Eye Infections
RB PDAT is a non-invasive investigational treatment that combines Provectus’s pharmaceutical-grade RBS with a light-based medical device developed by the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (BPEI), part of the University of Miami's Miller School of Medicine. This therapy targets eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Dominic Rodrigues, acting CEO of VisiRose (search), highlighted the potential impact of RB PDAT: "RB PDAT represents a consequential solution for patients at risk of vision loss from infectious keratitis (search). We believe this innovative therapy combines precise infection-fighting capabilities with vision-preserving benefits, paving the way for a brighter future for those struggling with this challenging condition."
Strategic Business Model
Ed Pershing, Chairman of the Boards of Directors of VisiRose (search) and Provectus, emphasized the strategic rationale behind this move: "VisiRose exemplifies Provectus’s forward-thinking business model, bridging innovation and impact. Spinning off this clinical-stage, ophthalmology-focused entity enhances our ability to address unmet medical needs while unlocking value for our stockholders. By focusing on a high-growth area like eye care, we are both advancing RB PDAT and maximizing the intrinsic value of RBS and, ultimately, Provectus’s market position."
About VisiRose and Provectus
VisiRose (search) is a clinical-stage biotechnology company focused on commercializing ocular research from the Bascom Palmer Eye Institute, utilizing Provectus’s Rose Bengal Sodium (RBS). Provectus Biopharmaceuticals (search) is developing immunotherapy medicines based on halogenated xanthenes for various diseases. More information about VisiRose can be found at https://visirose.com/.